• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)
临床输血与检验

临床输血与检验 ›› 2018, Vol. 20 ›› Issue (6): 632-634.DOI: 10.3969/j.issn.1671-2587.2018.06.024

• 临床检验 • 上一篇    下一篇

重组人血小板生成素治疗血液肿瘤化疗所致血小板减少症疗效

孙少勤   

  1. 073000 河北省定州市人民医院血液科
  • 收稿日期:2018-04-13 出版日期:2018-12-20 发布日期:2018-11-12
  • 作者简介:孙少勤（1968-）,女,河北定州人,副主任医师,本科,主要从事血液学研究,（Tel）13560188581。

A Therapeutic Effect of Recombinant Thrombopoietin on Thrombocytopenia Caused by Leukemia Chemotherapy

SUN Shao-qin   

  1. Depatment of Hematology, Hebei Province Dingzhou People's Hospital,Dingzhou 073000
  • Received:2018-04-13 Online:2018-12-20 Published:2018-11-12

PDF

947

摘要： 目的 分析重组人血小板生成素（rhTPO）在血液肿瘤化疗后血小板减少症（CIT）治疗中的应用价值。方法 将110例血液肿瘤CIT患者随机分为两组,以接受白细胞介素（IL）-11治疗者为对照组,以接受rhTPO治疗者为观察组,每组55例。分析两组治疗过程中血小板计数（PLT）及相关炎性因子的变化情况。结果 治疗前后两组PLT呈先降后升趋势,IL-4及IL-8呈先升后降趋势（P<0.05）。虽然两组入组时及治疗2 d后,PLT、IL-4及IL-8比较差异无统计学意义（P>0.05）,而治疗7 d及14 d后,观察组PLT高于对照组,IL-4及IL-8低于对照组,差异有统计学意义（P<0.05）。同时,完全14 d治疗后,观察组治疗总有效率高于对照组,差异有统计学意义（P<0.05）。此外,在14 d治疗过程中,两组不良反应发生率比较,差异无统计学意义（P>0.05）。结论 相对于IL-11治疗,rhTPO可更有效的提高血液肿瘤CIT的治疗效果。

关键词: 重组人血小板生成素, 血液肿瘤, 化疗血小板减少, 炎性因子

Abstract: Objective To analyze the practical value of the recombinant human thrombopoietin（rhTPO） in the treatment of thrombocytopenia induced by blood tumor chemotherapy. Methods One hundred and ten patients with thrombocytopenia induced by blood cancer treatment were randomly divided into two groups,with 55 cases in each. The patients of control group received only IL-11 treatment and those of observation group were given rhTPO. Platelet count（PLT） and inflammatory cytokines were detected. Results All patients showed a primary PLT decrease followed by an increase before and after treatments,while IL-4 and IL-8 levels were elevated early and reduced gradually（P<0.05）. The PLT level was found to be increased but IL-4 and IL-8 decreased in observation group after 7 and 14 days of treatments（P<0.05）. As a result,the total effective rate of the observation group was notably higher than those of the control after 14 days of treatments（P<0.05）. However,no difference of the adverse reactions was seen between the two groups（P>0.05）. Conclusion Compared with IL-11,rhTPO is more effective for the treatment of thrombocytopenia caused by leukemia chemotherapy.

Key words: Recombinant thrombopoietin, Leukemia, Thrombocytopenia chemotherapy, Inflammatory cytokine